The E-selectin antagonist uproleselan showed preclinical efficacy in sensitizing AML cells to standard chemotherapeutic agents [200], and a recent phase I/II study in adults with R/R AML and elderly patients with newly diagnosed (ND) AML (phase II only) was recently published [201]. Here, SELE is linked to acute myeloid leukemia.